Evidence map›Paper›PMID 42553684›Full record

ArticleFrontiers in cardiovascular medicine2026

Clinical outcomes of Impella 5+ in acute myocardial infarction-related cardiogenic shock: a retrospective single-center study.

Giulia Maj, Alberto Piermartiri, Serena Querio, Marta Bandini, Marco Lombardi, Edoardo Elia, Serena Penpa, Riccardo Mazzucco, Federico Pappalardo, Corrado Cavozza and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Giulia Maj *Cardiothoracic and Vascular Anesthesia and Intensive Care, AOU SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
Alberto Piermartiri *Cardiology Department, IRCCS Policlinico Sant'Orsola, University Hospital of Bologna, Bologna, Italy.
Serena QuerioCardiothoracic and Vascular Anesthesia and Intensive Care, AOU SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
Marta BandiniCardiothoracic Intensive Care Department, Royal Papworth Hospital, Cambridge, United Kingdom.
Marco LombardiInterventional Cardiology Department and Cardiac Surgery Unit, AOU SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
Edoardo EliaInterventional Cardiology Department and Cardiac Surgery Unit, AOU SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
Serena PenpaResearch and Innovation Department (DAIRI), University Hospital SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
Riccardo MazzuccoResearch and Innovation Department (DAIRI), University Hospital SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
Federico PappalardoKore University, Enna, Italy.
Corrado CavozzaCardiac Surgery Department, AOU SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
Alina GalloCardiac Surgery Department, AOU SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
Andrea AudoCardiac Surgery Department, AOU SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
Giuseppe PattiDepartment of Traslational Medicine, Univeristy of Eastern Piedmont, Novara, Italy.
Gioel Gabrio SeccoInterventional Cardiology Department and Cardiac Surgery Unit, AOU SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Temporary mechanical circulatory support (t-MCS) with Impella CP has recently attracted considerable interest as a therapeutic option for cardiogenic shock (CS) complicating acute myocardial infarction (AMI). In contrast, evidence regarding the use of the larger Impella 5+ (5.0/5.5) in this clinical setting remains limited. This single-centre retrospective study aimed to evaluate the clinical impact of Impella 5+ in patients with AMI-related cardiogenic shock (AMI-CS). Methods and results: Between January 2022 and August 2024, 28 patients referred for AMI-CS were treated with Impella 5+. 11 patients were classified as SCAI C, 11 as SCAI D and 6 as SCAI E. On admission, median inotropic score was 10.5 and median left ventricular ejection fraction was 17.5%. 12 patients required concomitant ECMO support (ECPella). 19 patients were escalated from IABPM to Impella 5+. The median length of support was 8 days, 2 patients (7%) received the support for more than 30 days. 1 patient experienced a major bleeding complication. The overall survival during index hospitalization was 79%: 3 patients were bridged to a durable left ventricular assist device (LVAD) and 2 received heart transplantation (HTx). Conclusions: Impella 5+ appears to be a safe and effective option in AMI-CS, associated with improved survival and a relatively low incidence of vascular and non-vascular complications. Its advanced features broaden the therapeutic potential of microaxial flow pumps in this high-risk setting.

Indexed as

cardiogenic shockheart failureimpellaimpella 5+ischemicmechanical circulatory (MCS) support

Identifiers

PMID42553684
PMCPMC13435220

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.